Financial Statements

Novartis AG (NVS)

$89.42

+0.77 (+0.87%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -----
Net Income 24,0218,07211,73212,6117,703
Stock Dividends -16,653-1,085-5,087-5,645-1,208
Dividend Paid -7,368-6,987-6,645-6,966-6,495
Retained Earnings -----

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 13,93913,74615,69616,464-
Annual Depreciation 2,1382,7783072,58719,210
Capital Expenditure -2,971-2,585-2,257-3,355-2,746
Net PPE 13,10613,93913,74615,69616,464

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -31,75035,29426,52429,999
New Purchases -1,048-2,702-530-2,130-16,594
Intangible and Goodwill 31,75035,29426,52429,99929,595

Novartis AG income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Novartis AG FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.